Avidity Biosciences has been granted a patent for compositions and pharmaceutical formulations containing a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. The patent also covers methods for treating diseases using these compositions. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of May 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Therapeutic composition for treating diseases using modified polynucleic acid
A recently granted patent (Publication Number: US12006499B2) discloses a compound with a specific chemical structure outlined in Formula (II). The compound, along with its pharmaceutically acceptable salt or solvate, is characterized by the presence of various substituents denoted by R1, R2, R3, and Ring G. Notably, R1 is specified as —OCH2C(-O)NR7R7, where R7 can be hydrogen or substituted/unsubstituted C1-C3 alkyl. Additionally, R2 is defined as isopropyl, and specific configurations involving R2 and the nitrogen atom are detailed in the claims.
Furthermore, the patent emphasizes the importance of the compound's structural elements, such as Ring G and X (Oxygen), in conjunction with the presence of 4,4'-dimethoxytrityl (DMT) as R3. The claims also elaborate on the potential formation of heterocycloalkyl structures through the interaction of R2 with the nitrogen atom. These detailed specifications aim to protect the unique chemical composition and potential pharmaceutical applications of the disclosed compound and its derivatives. Overall, the patent provides a comprehensive framework for the synthesis and utilization of this compound in various pharmaceutical contexts, highlighting its potential as a valuable addition to the field of medicinal chemistry.
To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
